- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06305676
Biomarkørtilgang til screening for tidlig påvisning af HPV-relateret oropharyngeal cancer (BASH OPC) (BASH OPC)
Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Kimberly Isaacs-Soriano
- Telefonnummer: 813-745-6992
- E-mail: kimberly.Isaacs-Soriano@moffitt.org
Studiesteder
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Underforsker:
- Christine Chung, MD
-
Kontakt:
- Kimberly Isaacs-Soriano
- Telefonnummer: 813-745-6992
- E-mail: kimberly.Isaacs-Soriano@moffitt.org
-
Ledende efterforsker:
- Anna Giuliano, PhD
-
Ledende efterforsker:
- Antonio Amelio, PhD
-
Underforsker:
- Jimmy Caudell, MD, PhD
-
Underforsker:
- Bruce Wenig, MD
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
-
Kontakt:
- Jose P. Zevallos, MD, PhD
- E-mail: zevallosjp@upmc.edu
-
Kontakt:
- Robert Ferris, PhD
- E-mail: ferrrl@UPMC.EDU
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The study population will consist of 100 early and 100 late disease pre-treatment Oropharyngeal Cancer cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh).
Beskrivelse
Inclusion Criteria:
Cases:
- Aged at least 18 years
- Newly diagnosed primary tumor, histologically confirmed squamous cell carcinoma of the oropharynx (stages I-IV)
- Has not received treatment (surgery, chemotherapy, radiation, or immunotherapy) within the previous four weeks
- Provided written informed consent under Moffitt Cancer Center (MCC) 17716 biomarker/biobanking study or is identified and enrolled at the University of Pittsburgh Medical Center Hillman Cancer Center
- Aged at least 35 years
- Have no previous diagnosis of HNC or HPV-related cancer
- Fully understands study procedures
- Voluntarily agrees to participate by giving written informed consent under Moffitt Cancer Center (MCC) 17716 biomarker/biobanking study or is enrolled at the University of Pittsburgh Medical Center Hillman Cancer Center
Exclusion Criteria:
- Not meeting all of the above inclusion criteria for either the case or control group
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Case Group
Case group will consist of early and late disease pre-treatment Oropharyngeal Cancer cases. |
DNA Methylation Profiling |
|
Control Group
Controls will be enrolled from members of the catchment area to ensure geographic comparability of cases and controls. Controls will be matched by sex, age, race/ethnicity, and tobacco use. |
DNA Methylation Profiling |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Sensitivity
Tidsramme: Up to 60 months
|
A 95% one-sided confidence interval using the Wilson method will be obtained for sensitivity for the early Oropharyngeal Cancer cases and late Oropharyngeal Cancer cases. |
Up to 60 months
|
|
Diagnostic Specificity
Tidsramme: Up to 60 months
|
A 95% one-sided confidence interval using the Wilson method will be obtained for Specificity based on the control patients. |
Up to 60 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Anna Giuliano, PhD, Moffitt Cancer Center
- Ledende efterforsker: Antonio Amelio, PhD, Moffitt Cancer Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MCC-23073
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .